India's Answer to Diabetic Foot Ulcer: IPCA Launches Diulcus

IPCA Laboratories Ltd announces the launch of Diulcus, a new treatment for Diabetic Foot Ulcer (DFU) in India. Developed by NovaLead Pharma Pvt Ltd, Diulcus has demonstrated significant efficacy in phase 3 trials and has received CDSCO approval. The launch reflects IPCA’s dedication to addressing unmet medical needs.

In a significant move towards addressing one of India's pressing healthcare challenges, IPCA Laboratories Ltd has launched Diulcus, a novel treatment aimed at managing Diabetic Foot Ulcer (DFU). Diulcus, developed by NovaLead Pharma Pvt Ltd, is a breakthrough in DFU management, supported by a 60.3% ulcer closure rate within three months in phase 3 trials.

Esteemed figures like Sri. Premchand Godha and Dr. Anil Pareek attended the launch event, highlighting the importance of this medical advancement. Diulcus has received formal approval from the Central Drugs Standard Control Organization (CDSCO) and partial funding from BIRAC.

Mr. Premchand Godha underscored the importance of the drug, stating that 15% of diabetic patients suffer from DFU at least once in their lifetime, making it the leading cause of lower limb amputations globally. Diulcus will be available in India starting August 2024 through an exclusive IP licensing arrangement between IPCA and NovaLead.

(With inputs from agencies.)